Articles
January 12, 2021 – Taiho Oncology and Servier to Present Data on LONSURF® (trifluridine and tipiracil) at 2021 ASCO Gastrointestinal Cancers Symposium
PRINCETON, N.J., January 12, 2021 – Taiho Oncology, Inc. and Servier today announced that data for LONSURF® (trifluridine and tipiracil) in previously treated patients with metastatic gastric cancer (mGC) and metastatic gastroesophageal junction adenocarcinoma (mGEJC) will be presented during the 2021 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI), taking place virtually from…
Read MoreNovember 1, 2020 – Taiho Oncology Joins Advocacy Organizations to Support Patients and Caregivers During Gastric Cancer Awareness Month
Taiho Oncology, Inc., today announced partnerships with advocacy organizations on education programs and resources to support patients living with gastric (stomach) cancer and their caregivers as part of Gastric Cancer Awareness Month (GCAM). Patients with stomach cancer require nutritious foods in order to help them recover from treatment and maintain strength; the pandemic has had…
Read MoreMarch 20, 2020 – Care of Individuals with Cancer During COVID-19
ASCO invited its members to submit questions about issues and challenges they see emerging while caring for individuals with cancer in the context of the coronavirus pandemic. Currently, limited clinical cancer-specific data are available and information is evolving. The following information is based on evidence gathered through a PubMed searches of the medical literature, a…
Read MoreJanuary 30, 2020 – Family History of Gastric Cancer and Helicobacter Pylori Treatment
Helicobacter pylori infection and a family history of gastric cancer are the main risk factors for gastric cancer. Whether treatment to eradicate H. pylori can reduce the risk of gastric cancer in persons with a family history of gastric cancer in first-degree relatives is unknown. View Full Article
Read MoreJanuary 15, 2020 – Early-Onset Gastric Cancer, Distinct From Traditional Disease, On The Rise In US
Incidence of early-onset gastric cancer that is clinically and genetically distinct from late-onset disease has increased steadily in the United States, an “alarming phenomenon” that warrants further research, according to a study published in Surgery. “There is an increasing trend of young patients diagnosed with gastric cancer, but without any of the traditional risk factors…
Read MoreJanuary 6, 2020 – Leap, BeiGene to Develop Immunotherapy for Gastric Cancer
US based Leap Therapeutics, Inc. a biotechnology company developing targeted immuno-oncology therapeutics, and China headquartered BeiGene, Ltd., a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, on 3 Jan 2020 announced an exclusive option and license agreement for the clinical development and commercialization of DKN-01,…
Read MoreNovember 1, 2019 – Taiho Oncology Joins Efforts To Improve Awareness Of Gastric Cancer With Support Of Leading Advocacy Groups
Recognizing a need for greater awareness and education around gastric cancer, Taiho Oncology, Inc., today announced its support of four leading gastric cancer advocacy organizations in observance of National Gastric Cancer Awareness Month. The company is sponsoring patient and caregiver programs, education and research throughout 2019 on behalf of Debbie’s Dream Foundation, the Gastric Cancer…
Read MoreOctober 14, 2019 – ANALYSIS OF PATIENTS WITH PRIOR GASTRECTOMY TREATED WITH LONSURF® (TRIFLURIDINE AND TIPIRACIL) PUBLISHED IN JAMA ONCOLOGY
Taiho Oncology, Inc. announced today that detailed results from the analysis of patients with prior gastrectomy enrolled in the Phase 3 TAS-102 Gastric Study (TAGS) evaluating LONSURF® (trifluridine and tipiracil) in adult patients with metastatic gastric or gastroesophageal junction adenocarcinoma previously treated with at least two prior lines of chemotherapy that included a fluoropyrimidine, a platinum, either a taxane…
Read MoreJuly 3, 2019 – Gastric Cancer Rates Higher Among Patients Treated For H. Pylori
Patients who receive antibiotic treatment for Helicobacter pylori infection experience gastric cancer at rates higher than the general population and several risk factors can increase that risk even further, according to data presented at Digestive Disease Week. View Full Article
Read MoreJuly 4, 2019 – Study Uncovers Origin of Cell Layer that Hides Stomach Cancer
A group of researchers from Hiroshima recently discovered the origin of a normal-looking stomach lining that covers sites of gastric cancer and makes it difficult to spot after the eradication of an H. pylori infection. H. pylori infection is a major cause of stomach cancer and causes inflammation by releasing substances that can destroy cells…
Read More